Stoke Therapeutics (STOK) Accumulated Expenses (2018 - 2026)

Stoke Therapeutics' Accumulated Expenses history runs 9 years deep, the most recent figure standing at $3.1 million for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 87.36% year-over-year to $3.1 million; the TTM figure through Mar 2026 stood at $3.1 million (down 87.36% YoY), while the FY2025 annual figure was $41.0 million, up 121.01% from the prior year.
• Accumulated Expenses was $3.1 million for Q1 2026 at Stoke Therapeutics, down from $41.0 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $41.0 million in Q4 2025 to a low of $1.5 million in Q1 2023.
• Historically, Accumulated Expenses has averaged $11.8 million across 5 years, with a median of $7.2 million in 2025.
• The sharpest annual moves came in 2022 and 2026: Accumulated Expenses soared 929.47% in 2022, then tumbled 87.36% in 2026.
• A 5-year view of Accumulated Expenses shows it stood at $5.8 million in 2022, then fell by 2.49% to $5.6 million in 2023, then soared by 230.9% to $18.6 million in 2024, then soared by 121.01% to $41.0 million in 2025, then slumped by 92.5% to $3.1 million in 2026.
• The last three Accumulated Expenses figures came in at $3.1 million (Q1 2026), $41.0 million (Q4 2025), and $7.2 million (Q3 2025), per Business Quant data.